◆英語タイトル:Sandoz Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3439
◆発行会社(調査会社):
GlobalData
◆発行日:2018年8月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Sandoz Inc (Sandoz), a division of Novartis AG (Novartis), is a generic pharmaceutical company that develops, manufactures and distributes and sells a range of prescription medicines and protein and biosimilars. The company also provides intermediary products including active pharmaceutical ingredients (APIs), as well as biotechnology manufacturing services to other companies. It provides active ingredients and finished dosage forms of pharmaceuticals in the areas of dermatology, cancer, cardiovascular, respiratory, metabolism, central nervous system (CNS), pain, ophthalmic, gastrointestinal and hormonal therapies. Sandoz distributes its products to wholesalers, pharmacies, hospitals and other healthcare outlets. Sandoz is headquartered in Princeton, New Jersey, the US.
Sandoz Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sandoz Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sandoz Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sandoz Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sandoz Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Fougera Pharma Acquires US Rights to Veregen from Medigene 11
Partnerships 12
Pear Therapeutics Enters into Agreement with Sandoz 12
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 13
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 14
Fougera Pharma Enters into Co-Promotion Agreement with Women’s Choice Pharma for Veregen 15
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 16
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 17
Licensing Agreements 19
Sandoz and Beximco Pharma Enter into Licensing Agreement with Medicines Patent Pool 19
BioQuiddity Expands Licensing Agreement with Sandoz 20
Asset Transactions 21
CASI Pharma Acquires ANDA Portfolio from Sandoz 21
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 22
Upsher-Smith Labs Acquires 20 US Generic Products from Sandoz 23
Acquisition 24
Novartis Completes Acquisition Of Fougera Pharma, Dermatology Company, For US$1.5 Billion 24
Sandoz Inc – Key Competitors 26
Sandoz Inc – Key Employees 27
Sandoz Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Strategy And Business Planning 29
Oct 16, 2017: Novartis to Shut Broomfield Generics Manufacturing Unit, Eliminate 450 Jobs 29
Legal and Regulatory 30
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 30
Product News 31
Jul 06, 2018: Novartis and Sandoz withdraw medicines from US over packaging concerns 31
Jul 06, 2018: Sandoz and its affiliate, Novartis Pharmaceuticals voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance 32
Mar 26, 2018: TU Wien: Digital penicillin production 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Sandoz Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sandoz Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sandoz Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sandoz Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sandoz Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fougera Pharma Acquires US Rights to Veregen from Medigene 11
Pear Therapeutics Enters into Agreement with Sandoz 12
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 13
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 14
Fougera Pharma Enters into Co-Promotion Agreement with Women’s Choice Pharma for Veregen 15
PharmaDerm and MediGene Enter into Agreement with Women’s Choice Pharma 16
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 17
Sandoz and Beximco Pharma Enter into Licensing Agreement with Medicines Patent Pool 19
BioQuiddity Expands Licensing Agreement with Sandoz 20
CASI Pharma Acquires ANDA Portfolio from Sandoz 21
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 22
Upsher-Smith Labs Acquires 20 US Generic Products from Sandoz 23
Novartis Completes Acquisition Of Fougera Pharma, Dermatology Company, For US$1.5 Billion 24
Sandoz Inc, Key Competitors 26
Sandoz Inc, Key Employees 27
Sandoz Inc, Other Locations 28
Sandoz Inc, Subsidiaries 28
List of Figures
Sandoz Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sandoz Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sandoz Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sandoz Inc, Medical Devices Deals, 2012 to YTD 2018 9